Press release
Odense, Denmark – September 22, 2025 – Inverna Therapeutics will participate at the Nordic Life Science Days (NLSDays) 2025, taking place October 13–14 in Gothenburg, Sweden. As the premier Nordic event for life science innovation and collaboration, NLSDays gathers top researchers, industry leaders, and investors to shape the future of healthcare.
“We are honored that Inverna has been selected for the Nordic Star Pitch Competition” says Poul Sørensen, CEO. “We look forward to sharing our progress in developing ultra precise oligonucleotide RNA therapeutics that modulate gene expression through precise pseudo-exon activation, designed to maximize efficacy while minimizing off target effects.”
Inverna welcomes the opportunity to connect and provide further details about our innovative therapeutic programs. Reach out via the partnering platform and schedule a one-on-one meeting during the event.
About Inverna Therapeutics Inverna Therapeutics is a Danish biotech company, founded in 2024 and based in Odense. With its proprietary drug discovery platform, Inverna is dedicated to developing transformative RNA therapeutics based on RNA splicing modulation. The company aims to rapidly design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. With a strong scientific foundation and an experienced, talented team, Inverna is committed to advancing novel RNA therapeutics and bringing hope to patients.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
